Sangamo Therapeutics Stock Market Capitalization
| SGMO Stock | USD 1.94 0.06 3.19% |
Sangamo Therapeutics fundamentals help investors to digest information that contributes to Sangamo Therapeutics' financial success or failures. It also enables traders to predict the movement of Sangamo Stock. The fundamental analysis module provides a way to measure Sangamo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangamo Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Market Cap | 85.3 M | 81 M |
Sangamo | Market Capitalization |
Sangamo Therapeutics Company Market Capitalization Analysis
Sangamo Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Sangamo Therapeutics Market Capitalization | 563.24 M |
Most of Sangamo Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sangamo Market Capitalization Driver Correlations
Understanding the fundamental principles of building solid financial models for Sangamo Therapeutics is extremely important. It helps to project a fair market value of Sangamo Stock properly, considering its historical fundamentals such as Market Capitalization. Since Sangamo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sangamo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sangamo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Sangamo Market Capitalization Historical Pattern
Today, most investors in Sangamo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sangamo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's market capitalization growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sangamo Therapeutics market capitalization as a starting point in their analysis.
Sangamo Therapeutics Market Capitalization |
| Timeline |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of Sangamo Therapeutics is about 563.24 M. This is 95.65% lower than that of the Biotechnology sector and 88.12% lower than that of the Health Care industry. The market capitalization for all United States stocks is 97.04% higher than that of the company.
Sangamo Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangamo Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sangamo Therapeutics could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics of similar companies.Sangamo Therapeutics is currently under evaluation in market capitalization category among its peers.
Sangamo Fundamentals
| Return On Equity | -1.94 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (94.13) % | ||||
| Current Valuation | 380.78 M | ||||
| Shares Outstanding | 208.22 M | ||||
| Shares Owned By Insiders | 2.38 % | ||||
| Shares Owned By Institutions | 38.53 % | ||||
| Number Of Shares Shorted | 18.98 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 10.02 X | ||||
| Price To Sales | 7.50 X | ||||
| Revenue | 176.23 M | ||||
| Gross Profit | (138.6 M) | ||||
| EBITDA | (87.43 M) | ||||
| Net Income | (257.83 M) | ||||
| Cash And Equivalents | 315.72 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 38.1 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (224.84 M) | ||||
| Short Ratio | 1.92 X | ||||
| Earnings Per Share | (1.24) X | ||||
| Target Price | 4.8 | ||||
| Number Of Employees | 405 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 563.24 M | ||||
| Total Asset | 165.32 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46.6 M | ||||
| Current Asset | 212.58 M | ||||
| Current Liabilities | 20.1 M | ||||
| Net Asset | 165.32 M |
About Sangamo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangamo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangamo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangamo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sangamo Stock
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.83 | MTEM | Molecular Templates | PairCorr |
| 0.8 | AGL | agilon health Buyout Trend | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.76 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.